{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:19:56Z","timestamp":1788502796673,"version":"build-2803163510"},"reference-count":93,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty Evaluation Development","award":["15096"],"award-info":[{"award-number":["15096"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Immune checkpoint inhibitors, introduced in recent years, have revolutionized the treatment of many cancers. However, the toxicity associated with this therapy may cause severe adverse events. In the case of advanced lung cancer or metastatic melanoma, a significant number (10%) of patients treated with CTLA-4 inhibitor incur damage to the pituitary gland. In order to reduce the risk of hypophysitis and other severe adverse events, steroids may be combined with CTLA-4 inhibitor; they reduce toxicity, but they also diminish the anti-cancer effect of the immunotherapy. This trade-off between tumor reduction and the risk of severe adverse events poses the following question: What is the optimal time to initiate treatment with steroid. We address this question with a mathematical model from which we can also evaluate the comparative benefits of each schedule of steroid administration. In particular, we conclude that treatment with steroid should not begin too early, but also not very late, after immunotherapy began; more precisely, it should start as soon as tumor volume, under the effect of CTLA-4 inhibitor alone, begins to decrease. We can also compare the benefits of short term treatment of steroid at high doses to a longer term treatment with lower doses.<\/jats:p>","DOI":"10.1371\/journal.pone.0277248","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T18:37:47Z","timestamp":1668105467000},"page":"e0277248","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3005-8508","authenticated-orcid":true,"given":"Nourridine","family":"Siewe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7875-174X","authenticated-orcid":true,"given":"Avner","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"issue":"1","key":"pone.0277248.ref001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","article-title":"Toxicities Associated With PD-1\/PD-L1 Blockade","volume":"24","author":"DY Wang","year":"2018","journal-title":"Cancer J"},{"issue":"Suppl 3","key":"pone.0277248.ref002","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.21037\/jtd.2018.01.111","article-title":"Identifying and managing the adverse effects of immune checkpoint blockade","volume":"10","author":"A Winer","year":"2018","journal-title":"J Thorac Dis"},{"key":"pone.0277248.ref003","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S57335","article-title":"Ipilimumab in the treatment of metastatic melanoma: management of adverse events","volume":"7","author":"GDV Scarpati","year":"2014","journal-title":"OncoTargets and therapy"},{"issue":"3","key":"pone.0277248.ref004","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5306\/wjco.v12.i3.150","article-title":"Systemic adverse effects and toxicities associated with immunotherapy: A review","volume":"12","author":"A Kichloo","year":"2021","journal-title":"World J Clin Oncol"},{"issue":"1","key":"pone.0277248.ref005","doi-asserted-by":"crossref","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"G Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"issue":"1","key":"pone.0277248.ref006","article-title":"Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK","volume":"5","author":"ACP So","year":"2018","journal-title":"Melanoma Manag"},{"issue":"1","key":"pone.0277248.ref007","doi-asserted-by":"crossref","first-page":"e000477","DOI":"10.1136\/esmoopen-2018-000477","article-title":"Early use of steroids affects immune cells and impairs immunotherapy efficacy","volume":"4","author":"CM Della Corte","year":"2019","journal-title":"ESMO Open"},{"issue":"5","key":"pone.0277248.ref008","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archinte.1984.00350170119021","article-title":"Prednisone and T-Cell Subpopulations","volume":"144","author":"MR Schuyler","year":"1984","journal-title":"Arch Intern Med"},{"issue":"1","key":"pone.0277248.ref009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"AJ Giles","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"pone.0277248.ref010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/qjmed\/93.6.323","article-title":"The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia","volume":"93","author":"TM O\u2019Connor","year":"2020","journal-title":"QJM"},{"issue":"10","key":"pone.0277248.ref011","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3390\/cancers12102827","article-title":"Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)","volume":"12","author":"A De Giglio","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"28","key":"pone.0277248.ref012","first-page":"2872","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung","volume":"36","author":"KC Arbour","year":"2018","journal-title":"Cancer J Clin Oncol"},{"issue":"e002261","key":"pone.0277248.ref013","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"DV Maslov","year":"2021","journal-title":"J ImmunoTher Cancer"},{"issue":"3","key":"pone.0277248.ref014","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"12","author":"F Petrelli","year":"2020","journal-title":"Cancers"},{"issue":"108","key":"pone.0277248.ref015","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-\u03b1 production","volume":"11","author":"S Laurent","year":"2013","journal-title":"J Transl Med"},{"key":"pone.0277248.ref016","doi-asserted-by":"crossref","first-page":"9551","DOI":"10.2147\/CMAR.S224791","article-title":"Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies","volume":"12","author":"M Tsoli","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"pone.0277248.ref017","article-title":"Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population","volume":"6","author":"KZ Wei","year":"2019","journal-title":"Melanoma Manag"},{"issue":"27","key":"pone.0277248.ref018","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"F Castillero","year":"2019","journal-title":"Future Oncol"},{"issue":"3","key":"pone.0277248.ref019","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5603\/EP.a2019.0015","article-title":"Hypophysitis\u2014new insights into diagnosis and treatment","volume":"70","author":"L Kluczy\u0144ski","year":"2019","journal-title":"Endokrynol Pol"},{"issue":"5","key":"pone.0277248.ref020","first-page":"266","article-title":"Regulation of pituitary function by cytokines","volume":"72","author":"MR Haedo","year":"2009","journal-title":"Horm Res"},{"issue":"12","key":"pone.0277248.ref021","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series","volume":"186","author":"P Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"3","key":"pone.0277248.ref022","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"MN Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"pone.0277248.ref023","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-17-0009","article-title":"MECHANISMS IN ENDOCRINOLOGY: Hypophysitis: diagnosis and treatment","volume":"179","author":"MN Joshi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"43492","key":"pone.0277248.ref024","article-title":"In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis","volume":"7","author":"HH Lin","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0277248.ref025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.17925\/USE.2020.16.2.117","article-title":"An Update on Immune Checkpoint Inhibitor-related Hypophysitis","volume":"16","author":"MJ Mortensen","year":"2020","journal-title":"US Endocrinol"},{"issue":"3-4","key":"pone.0277248.ref026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000509081","article-title":"Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"106","author":"D K\u00f6nig","year":"2021","journal-title":"Pharmacology"},{"issue":"3","key":"pone.0277248.ref027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"A Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"pone.0277248.ref028","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00262-017-2071-2","article-title":"Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study","volume":"67","author":"D Franzen","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"1785","key":"pone.0277248.ref029","article-title":"Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation","volume":"10","author":"S Zhu","year":"2020","journal-title":"Front Oncol"},{"issue":"17324","key":"pone.0277248.ref030","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data","volume":"11","author":"T Makunts","year":"2021","journal-title":"Sci Rep"},{"issue":"20","key":"pone.0277248.ref031","first-page":"1","article-title":"In the Clinic Risks Reported for Neurologic Adverse Events with Two Cancer Immunotherapies","volume":"17","author":"K Samson","year":"2017","journal-title":"NeurologyToday"},{"issue":"2","key":"pone.0277248.ref032","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14309\/ajg.0000000000000497","article-title":"Checkpoint inhibitor-induced colitis","volume":"115","author":"E Bellaguarda","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"pone.0277248.ref033","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors","volume":"14","author":"H Seethapathy","year":"2019","journal-title":"Clin J Am Nephrol"},{"issue":"1","key":"pone.0277248.ref034","first-page":"49","article-title":"Management of Acute Pancreatitis Associated With Checkpoint Inhibitors","volume":"11","author":"BB Rogers","year":"2020","journal-title":"J Adv Pract Oncol"},{"issue":"6","key":"pone.0277248.ref035","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"E De Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"pone.0277248.ref036","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-803302-9.00008-7","article-title":"Chapter 8\u2014Modulating Inflammatory Cytokines: IL-1","author":"MS Gresnigt","year":"2016","journal-title":"Immune Rebalancing, The Future of Immunosuppression"},{"issue":"2","key":"pone.0277248.ref037","doi-asserted-by":"crossref","first-page":"695","DOI":"10.4049\/jimmunol.1403187","article-title":"The Importance of IL-6 in the Development of LAT-Mediated Autoimmunity","volume":"195","author":"SA O\u2019Brien","year":"2015","journal-title":"J Immunol"},{"key":"pone.0277248.ref038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"TNF activity and T cells","volume":"101","author":"AK Mehta","year":"2018","journal-title":"Cytokine"},{"issue":"5","key":"pone.0277248.ref039","first-page":"1","article-title":"Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model","volume":"12","author":"X Lai","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"pone.0277248.ref040","first-page":"1","article-title":"Combination therapy for melanoma with BRAF\/MEK inhibitor and immune checkpoint inhibitor: a mathematical model","volume":"11","author":"X Lai","year":"2017","journal-title":"BMC Systems Biology"},{"issue":"21","key":"pone.0277248.ref041","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1073\/pnas.1721559115","article-title":"Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors","volume":"115","author":"X Lai","year":"2018","journal-title":"PNAS"},{"issue":"2","key":"pone.0277248.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0192449","article-title":"Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model","volume":"13","author":"A Friedman","year":"2018","journal-title":"PLoS ONE"},{"issue":"30","key":"pone.0277248.ref043","first-page":"1","article-title":"How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?","volume":"13","author":"X Lai","year":"2019","journal-title":"BMC Syst Biol"},{"issue":"1","key":"pone.0277248.ref044","doi-asserted-by":"crossref","first-page":"e0262453","DOI":"10.1371\/journal.pone.0262453","article-title":"Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model","volume":"17","author":"N Siewe","year":"2022","journal-title":"PLoS ONE"},{"issue":"4","key":"pone.0277248.ref045","first-page":"1","article-title":"TNF-\u03b1 inhibitor reduces drug-resistance to anti-PD-1: A mathematical model","volume":"15","author":"X Lai","year":"2020","journal-title":"PLoS ONE"},{"issue":"6","key":"pone.0277248.ref046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0252620","article-title":"TGF-\u03b2 inhibition can overcome cancer primary resistance to PD-1 blockade: a mathematical model","volume":"16","author":"N Siewe","year":"2021","journal-title":"PLoS ONE"},{"issue":"4","key":"pone.0277248.ref047","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3934\/dcdsb.2020138","article-title":"Mathematical modeling of an immune checkpoint inhibitor and its synergy with an immunostimulant","volume":"26","author":"E Nikolopoulou","year":"2021","journal-title":"DCDS-B"},{"key":"pone.0277248.ref048","doi-asserted-by":"crossref","first-page":"25","DOI":"10.30707\/SPORA4.1Radunskaya","article-title":"Mathematical Modeling of Tumor Immune Interactions: A Closer Look at the Role of a PD-L1 Inhibitor in Cancer Immunotherapy","volume":"4","author":"A Radunskaya","year":"2018","journal-title":"Spora: A Journal of Biomathematics"},{"key":"pone.0277248.ref049","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11425-019-1648-6","article-title":"Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor","volume":"63","author":"X Lai","year":"2020","journal-title":"Sci China Math"},{"issue":"17","key":"pone.0277248.ref050","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-15-3567","article-title":"Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy","volume":"76","author":"R Serre","year":"2016","journal-title":"Cancer Res"},{"key":"pone.0277248.ref051","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1002\/1521-4141(200011)30:11<3171::AID-IMMU3171>3.0.CO;2-C","article-title":"Positive and negative regulation of IL-12 receptor expression of naive CD4+T cells by CD28\/CD152 co-stimulation","volume":"30","author":"H Yamane","year":"2000","journal-title":"Eur J Immunol"},{"issue":"7","key":"pone.0277248.ref052","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.172.7.3983","article-title":"IL-2, regulatory T cells, and tolerance","volume":"172","author":"BH Nelson","year":"2004","journal-title":"J Immunol"},{"key":"pone.0277248.ref053","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and Function of Interleukin-2 in T Lymphocytes","volume":"36","author":"SH Ross","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"pone.0277248.ref054","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5021\/ad.2013.25.2.135","article-title":"Insights into the transforming growth factor-beta signaling pathway in cutaneous melanoma","volume":"25","author":"CY Perrot","year":"2013","journal-title":"Ann Dermatol"},{"key":"pone.0277248.ref055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/ITT.S55415","article-title":"The role of regulatory t cells in cancer immunology","volume":"4","author":"TL Whiteside","year":"2015","journal-title":"Immunotargets Ther"},{"issue":"1","key":"pone.0277248.ref056","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jmcb\/mjr033","article-title":"TGF-\u03b2: the sword, the wand, and the shield of FOXP3(+) regulatory T cells","volume":"4","author":"DQ Tran","year":"2012","journal-title":"J Mol Cell Biol"},{"issue":"18","key":"pone.0277248.ref057","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1073\/pnas.1103782108","article-title":"CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis","volume":"108","author":"A McNally","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0277248.ref058","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","article-title":"Hmgb1 and rage in inflammation and cancer","volume":"28","author":"GP Sims","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"pone.0277248.ref059","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"J Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"211","key":"pone.0277248.ref060","first-page":"1","article-title":"Tlr4-dependent activation of dendritic cells by an hmgb1-derived peptide adjuvant","volume":"12","author":"R Saenz","year":"2014","journal-title":"J Transl Med"},{"issue":"1","key":"pone.0277248.ref061","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/jca.5046","article-title":"Dendritic cells in the cancer microenvironment","volume":"4","author":"Y Ma","year":"2013","journal-title":"J Cancer"},{"issue":"7","key":"pone.0277248.ref062","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","article-title":"Tumor-infiltrating dendritic cells in cancer pathogenesis","volume":"194","author":"JMT Janco","year":"2015","journal-title":"J Immunol"},{"issue":"10","key":"pone.0277248.ref063","doi-asserted-by":"crossref","first-page":"FSO608","DOI":"10.2144\/fsoa-2020-0070","article-title":"A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy","volume":"6","author":"T Krishnan","year":"2020","journal-title":"Future Sci OA"},{"key":"pone.0277248.ref064","unstructured":"RELX Group (TM). Interleukin 12: Interleukin-12 (IL-12) is a potent proinflammatory cytokine that enhances the cytotoxic activity of T lymphocytes and resting natural killer cells. Pediatric Surgery, Seventh Ed. 2012;217."},{"issue":"2","key":"pone.0277248.ref065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1073\/pnas.1812186116","article-title":"Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti\u2013CTLA-4 antibody","volume":"116","author":"D Ha","year":"2019","journal-title":"PNAS"},{"key":"pone.0277248.ref066","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41422-018-0011-0","article-title":"A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy","volume":"28","author":"X Du","year":"2018","journal-title":"Cell Res"},{"issue":"3","key":"pone.0277248.ref067","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/eji.200939261","article-title":"CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets","volume":"39","author":"CE Rudd","year":"2012","journal-title":"Eur J Immunol"},{"issue":"47","key":"pone.0277248.ref068","doi-asserted-by":"crossref","first-page":"E6506","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging","volume":"112","author":"RL Maute","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"pone.0277248.ref069","doi-asserted-by":"crossref","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","article-title":"Structure and interactions of the human programmed cell death 1 receptor","volume":"288","author":"X Cheng","year":"2013","journal-title":"J Biol Chem"},{"issue":"12","key":"pone.0277248.ref070","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids","volume":"216","author":"A Tokunaga","year":"2019","journal-title":"J Exp Med"},{"issue":"30","key":"pone.0277248.ref071","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1200\/JCO.2015.61.0030","article-title":"Safety of Infusing Ipilimumab Over 30 Minutes","volume":"33","author":"P Momtaz","year":"2015","journal-title":"J Clin Oncol"},{"key":"pone.0277248.ref072","unstructured":"RxList. YERVOY, Generic Name: ipilimumab injection. Accessed March 12, 2021; p. https:\/\/www.rxlist.com\/yervoy\u2013drug.htm."},{"key":"pone.0277248.ref073","unstructured":"Drugs com. How long does it take prednisone to get out of your system? https:\/\/www.drugs.com\/medical-answers\/prednisone-how-long-does-it-take-predesone-to-get-372449\/. Last updated on March 22, 2021."},{"key":"pone.0277248.ref074","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2020.09.032","article-title":"How to manage patients with corticosteroids in oncology in the era of immunotherapy?","volume":"141","author":"M Aldea","year":"2020","journal-title":"Eur J Cancer"},{"issue":"9","key":"pone.0277248.ref075","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/pros.23508","article-title":"A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases","volume":"78","author":"J Linxweiler","year":"2018","journal-title":"Prostate"},{"key":"pone.0277248.ref076","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S5855","article-title":"Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities","volume":"6","author":"C Lemech","year":"2012","journal-title":"Clin Med Insights Oncol"},{"issue":"12","key":"pone.0277248.ref077","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.4049\/jimmunol.176.12.7196","article-title":"In Situ Replication of Immediate Dendritic Cell (DC) Precursors Contributes to Conventional DC Homeostasis in Lymphoid Tissue","volume":"176","author":"J Diao","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"pone.0277248.ref078","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4049\/jimmunol.131.5.2158","article-title":"Population dynamics of T lymphocytes. Renewal rate and expansion in the peripheral lymphoid organs","volume":"131","author":"B Rocha","year":"1983","journal-title":"J Immunol"},{"issue":"8","key":"pone.0277248.ref079","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/bloodadvances.2019001248","article-title":"IL-2 enhances ex vivo\u2013expanded regulatory T-cell persistence after adoptive transfer","volume":"4","author":"SN Furlan","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"pone.0277248.ref080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","article-title":"In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2","volume":"134","author":"MT Lotze","year":"1985","journal-title":"J Immunol"},{"issue":"7","key":"pone.0277248.ref081","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1438800","article-title":"Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells","volume":"7","author":"K Jung","year":"2018","journal-title":"OncoImmunol"},{"issue":"4","key":"pone.0277248.ref082","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0195037","article-title":"Chronic Hepatitis B Virus and Liver Fibrosis: A Mathematical Model","volume":"13","author":"A Friedman","year":"2018","journal-title":"PLoS ONE"},{"key":"pone.0277248.ref083","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/db11-0727","article-title":"Potential Role of Tumor Necrosis Factor-\u03b1 in Downregulating Sex Hormone\u2013Binding Globulin","volume":"61","author":"R Simo","year":"2012","journal-title":"Diabetes"},{"issue":"9","key":"pone.0277248.ref084","first-page":"503","article-title":"Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use","volume":"37","author":"C Fellner","year":"2012","journal-title":"P & T"},{"key":"pone.0277248.ref085","unstructured":"Drugs com. Medrol Dosepak\u2014How long does a dose pack stay in your system? 2020."},{"key":"pone.0277248.ref086","doi-asserted-by":"crossref","first-page":"D512","DOI":"10.1093\/nar\/gku1267","article-title":"PhosphoSitePlus, 2014: mutations, PTMs and recalibrations","volume":"43","author":"PV Hornbeck","year":"2015","journal-title":"Nucleic Acids Research"},{"key":"pone.0277248.ref087","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/bit.260220504","article-title":"Estimation of diffusion coefficients of proteins","volume":"XXII","author":"ME Young","year":"1980","journal-title":"Biotech Bioeng"},{"key":"pone.0277248.ref088","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601814","article-title":"Serum levels of IL-6 and TNF-\u03b1 correlate with clinicopathological features and patient survival in patients with prostate cancer","volume":"90","author":"V Michalaki","year":"2004","journal-title":"Br J Cancer"},{"key":"pone.0277248.ref089","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 56842206, TGF-beta. PubChem, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/TGF-beta. Accessed January 24, 2021."},{"key":"pone.0277248.ref090","unstructured":"Abcam. Recombinant Anti-CTLA4 antibody [EPR1476] (ab134090). https:\/\/www.abcam.com\/ctla4-antibody-epr1476-ab134090html."},{"key":"pone.0277248.ref091","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 5755, Prednisolone. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Prednisolone. Accessed September 29, 2021."},{"issue":"11","key":"pone.0277248.ref092","doi-asserted-by":"crossref","first-page":"e1496881","DOI":"10.1080\/2162402X.2018.1496881","article-title":"Impact of curative radiotherapy on the immune status of patients with localized prostate cancer","volume":"7","author":"F Eckert","year":"2018","journal-title":"Oncoimmunol"},{"issue":"5","key":"pone.0277248.ref093","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3892\/etm.2011.286","article-title":"Serum cytokine profiles in patients with prostate carcinoma","volume":"2","author":"E Tazaki","year":"2011","journal-title":"Exp Ther Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T19:35:50Z","timestamp":1678563350000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277248"}},"subtitle":[],"editor":[{"given":"Albert","family":"R\u00fcbben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":93,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0277248","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}